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Reprinted from International Journal of Radiation Oncology*Biology*Physics, Volume 75, Edition
3, Wachsberger P, Burd R, Ryan A, Daskalakis C, Dicker AP: “Combination of Vandetanib,
Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model”, pages
843-853, November 1, 2009. Reprinted with Permission of Elseiver.
Purpose: The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed
in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT),
or irinotecan (CPT-11), as single therapies and in combination.
Methods and Materials: LoVo cells were injected subcutaneously into the right hind limb
(5x106 cells in 100μL phosphate-buffered saline) of athymic NCR NUM mice and tumors were
grown to a volume of 200–300mm3 before treatment. Vandetanib was administered at 50 mg/kg
daily orally for 14 days starting on Day 1. RT was given as three fractions (3x3 Gy) on Days 1,
2, and 3. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Tumor volumes were
measured on a daily basis and calculated by measuring tumor diameters with digital calipers in
two orthogonal dimensions.
Results: All three single treatments (vandetanib, CPT-11, and radiation) significantly slowed
LoVo colorectal tumor growth. Vandetanib significantly increased the antitumor effects of CPT-11
and radiation when given in combination with either of these treatments. These treatment
combinations resulted in a slow tumor growth rate during the 2 weeks of vandetanib administration.
The triple combination of vandetanib, CPT-11, and radiation produced the most marked improvement in response as observed by measurable shrinkage of tumors during the first week of treatment.
Conclusions: The tumor growth delay kinetics observed in this study of the LoVo colorectal
model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy
may be beneficial in tumors of this type. ©2009 Elsevier Inc.

Key Words: Vandetanib, Radiotherapy, CPT-11, LoVo colorectal cancer,
Angiogenesis inhibitor.

Introduction
Colorectal cancer (CRC) remains one of the leading causes of mortality worldwide. In recent years,
the most widely used chemotherapy for metastatic CRC, fluoropyrimidine (5-fluorouracil [5-FU]) in
combination with folinic acid, has been combined with newer, highly active cytotoxic agents. Among
these agents is the DNA topoisomerase I inhibitor, irinotecan (CPT-11),1 a potent DNA-targeting
drug used in patients with CRC that is refractory to treatment with fluorouracil and leucovorin.
This cytotoxic agent is, in turn, being combined with new molecular therapies targeting the tumor
vasculature and key signaling pathways controlling tumor cell proliferation, angiogenesis, and
survival in CRC. In this regard, the epidermal growth factor receptor (EGFR) plays an important
role in CRC tumor growth and progression,2 and cetuximab, a monoclonal antibody specific for
EGFR, has been approved for use in combination with CPT-11 in patients with EGFR-expressing CRC
refractory to CPT-11–based chemotherapy.3 In addition, bevacizumab, a monoclonal antibody

specific for vascular endothelial growth
factor (VEGF-A), a key player in tumor
angiogenesis in CRC as well as other solid
tumors, has been approved for the treatment
of metastatic CRC in combination with
intravenous 5-FU–based chemotherapies.4
Despite recent improvements in treatment
for CRC, a need still remains to improve the
performance of existing treatments and to
establish the optimum scheduling and dosing
of combined therapies.
Vandetanib (ZACTIMA) is an oral receptor
tyrosine kinase inhibitor that, in recombinant
enzyme assays, demonstrates potent activity
against vascular endothelial growth factor
receptor-2 (VEGFR-2) tyrosine kinase (the half
maximal inhibitory concentration [IC50]=40
nmol/L) with additional activity against
EGFR (IC50=500 nmol/L) and the rearranged
during transfection (RET) tyrosine kinases
(IC50=130nM) tyrosine kinases.5–8 Vandetanib
has orphan-drug status in the United States
and Europe for medullary thyroid cancer
(in which RET activity is important) and is
in Phase III development in non–small-cell
lung cancer and medullary thyroid cancer.
Phase II studies are ongoing to investigate its
efficacy in other tumor types, thyroid cancer,
hepatocellular carcinoma, and glioblastoma.
Vandetanib has been shown to enhance the
efficacy of radiotherapy in subcutaneous and
orthotopic tumor xenograft models.9–13 The
combination of vandetanib, radiation, and
current chemotherapeutic agents used in CRC
treatment has not been studied. Preclinical
demonstration of efficacy of a combination
protocol with novel agents plus radiation
is usually considered crucial before clinical
evaluation. The purpose of the present study was
to examine the effect of vandetanib on the radiation response of a colorectal tumor model when
administered in combination with CPT-11. It was
hypothesized that simultaneous inhibition of
VEGFR and EGFR by vandetanib in combination
with the cytotoxic agent CPT-11 would interact
to enhance radiation response and tumor control
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in the human LoVo colorectal tumor cell model. The LoVo colorectal model
expresses activated EGFR14, 15 and is highly vascularized and therefore is an
appropriate model to test the hypothesis.

Methods and Materials
Animal and tumor model
LoVo cell suspensions (5x106 cells in 100 μL phosphate buffered saline)
were implanted subcutaneously into the right hind limbs of 6- to 8week-old athymic NCR NUM mice (Taconic Farms, Hudson, NY). A
subcutaneous xenograft model was chosen to facilitate radiation dosing and ease of tumor measurements. Tumors were allowed to grow for
approximately 25 days, until reaching an approximate volume of 200–
300mm3 at the start of treatment (Day 1). All animals were randomized
among treatment groups.

Drug treatment
Vandetanib (AstraZeneca, Macclesfield, UK) was administered by oral
gavage at 50mg/kg daily for 14 days, starting on Day 1. Vandetanib
dosing in this study was based on previous pharmacokinetic studies in
mouse models predicting relevance of this dosing to clinical drug exposure in human patients.16 CPT-11 was given at 15mg/kg intraperitoneally
on Days 1 and 3.

Tumor measurement
Tumors were synchronized to be approximately 250 mm3 at the start of
treatment (Day 1) and were measured four to five times per week, for
up to 6 weeks of follow-up, or until they reached 2,000 mm3. Tumor
size was determined by direct measurement with calipers and calculated
by the formula: (smallest diameter2 x widest diameter)/2. Tumors were
not allowed to grow beyond 2,000 mm3 in accordance with Institutional
Animal Care and Use Committee regulations.

In vivo tumor necrosis
Tumors were collected from animals on Day 14 after the start of treatment for fixation and staining with hematoxylin and eosin. The area of
necrosis was evaluated by image analysis and expressed as the percentage
of the total tumor area.

Radiation treatment

Statistical analysis

Irradiation was performed on anesthetized mice using X-rays generated
by a PanTak, 310 kVe X-ray machine, 0.25mm Cu+1mm Al added filtration, at 125cGy/min. Dosimetry was performed by an in-the-beam ionization chamber calibrated against a primary standard. Corrections were
made daily for humidity, temperature, and barometric pressure. Mice
were anesthetized with a combination of ketamine and acepromazine

Tumor growth was analyzed via mixed-effects regression, as previously
described. The method was used because it does not depend on an
arbitrary end point target tumor size, but uses the repeated tumor size
measurements obtained over the entire study period, while appropriately
handling unbalanced data (i.e., different number of measurements for
different animals) and the correlation of each animal’s measurements
over time. Mixed-effects regression yields generalizable parameters of
interest (e.g., average daily tumor growth rate, tumor doubling time), and
can investigate treatment interactions and nonlinear patterns of tumor
growth. The base-10 logarithm of tumor volume was modeled as a function of time and treatment. Linear or quadratic growth curves over time
were fitted to the log-transformed data, depending on growth patterns
in each treatment group. All statistical analyses were conducted in SAS
9.2 (SAS Institute Inc., Cary, NC, 1999–2001).

CPT-11
RT
Vandetanib
CPT-11
+ RT
CPT-11
+ vandetanib
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Figure 1. Summary of treatment groups. LoVo cells were implanted
subcutaneously into the right hind limbs of athymic NCR NUM
male mice. Mice were randomized into eight experimental groups
(11–16 animals per group). Vandetanib was administered at 50 mg/
kg daily orally for 14 days, starting on Day 1. CPT-11 was given at
15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given
as three fractions (3x3 Gy) on Days 1, 2, and 3.

12

at a concentration of 37.5mg/kg and 0.2mg/kg, respectively, to provide
25–30 min of sedation. Each mouse was confined in a lead casing with
its tumor-bearing leg extended through an opening on the side to allow
the tumor to be irradiated locally. Radiation was administered as three
daily fractions of 3 Gy each on Days 1, 2, and 3. On days when radiation
was administered with vandetanib or CPT-1, vandetanib and CPT-11
were given approximately 2h before radiation, with vandetanib preceding
CPT-11 administration.
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The experiment involved three different treatments (vandetanib, CPT-11,
and radiotherapy), as described above and summarized in Fig. 1. Data
were collected from a total of 104 animals in eight experimental groups
(11–16 animals per group) and are summarized in Fig. 2. Starting
tumor sizes were comparable across groups, with geometric means
ranging from 230 to 257mm3 (p = 0.771). All treatments were well
tolerated in the animals with no observable loss of body weight.
The three single-treatment groups (CPT-11, radiation, or vandetanib),
as well as the combination of CPT-11 with radiation (Fig. 2) were
fitted to log-transformed curves, whereas the three remaining groups
that received combination treatments involving vandetanib showed
a significantly nonlinear tumor growth and were fitted to quadratic curves.
Figure 3 shows the measured geometric mean tumor size graphically over
time. Table 1 shows the corresponding calculated tumor growth parameters
(daily tumor growth rate and tumor doubling time). Table 2 shows p values
for group comparisons at 7, 14, and 21 days after start of treatment.
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Figure 2. Tumor growth curves in LoVo xenografts treated with vandetanib, irinotecan (CPT-11), and/or radiation. Individual mouse data are
shown for eight treatment groups (11–16 animals per group), along with fitted group curves. Vandetanib was administered at 50 mg/kg daily
orally for 14 days, starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given as three fractions
(3x3 Gy) on Days 1, 2, and 3.
The control group had an estimated average daily tumor growth rate
of 9.9%, corresponding to an average tumor doubling time of about
7 days (Table 1). All three single treatments resulted in a significant
inhibition of tumor growth, compared with the control group (average
daily tumor growth rates: CPT-11: 7.1%, p = 0.015; radiation: 5.6%,
p = 0.001; vandetanib: 5.0%, p = 0.001). Vandetanib inhibited tumor
growth significantly more than CPT-11 (p = 0.043), but not radiation
(p = 0.514); radiation and CPT-11 were not significantly different
(p = 0.139). The combination of CPT-11 with radiation produced a
daily tumor growth rate of 5.1%, which was significantly lower than
CPT-11 alone (p = 0.015) but comparable to radiation alone (p = 0.560).
There was no significant (additive) interaction between CPT-11 and
radiation (p = 0.105).

The remaining three groups that received treatment combinations
involving vandetanib (with either CPT-11 or radiation, or with both
CPT-11 and radiation), showed significant treatment interactions
(p = 0.001 for the interaction between vandetanib and CPT-11 and
between vandetanib and radiation) and nonlinear tumor growth patterns.
Compared with single-treatment groups, growth was significantly
delayed (and, in the triple-treatment combination, tumor volume
actually decreased) early on, but progressively accelerated later, although
it never exceeded that of the untreated controls (Fig. 3). Because of the
nonlinearity of tumor growth in these groups, tumor growth parameters
are not constant over time and comparisons depend on the time point
referenced. Table 2 shows p values for Days 7, 14, and 21.
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than for either radiation alone or vandetanib alone (p = 0.005 and
0.019, respectively). After 14 days, the tumor growth rate in the
combination group had accelerated to 3.4% and was only marginally
lower than for radiation alone and comparable to that for vandetanib
alone (p=0.080 and 0.212, respectively). By the third and fourth
weeks, tumor growth had become similar to that seen in the singletreatment groups (Fig. 3, Table 1).

Tumor Volume (mm3)

10,000

1,000

Despite delaying tumor growth in the initial weeks, the treatment
combinations induced only modest levels of tumor necrosis (10–20%),
with no significant differences between treatment groups (Fig. 4).

CTR
CPT-11
RT
VAN
CPT-11+RT
VAN+CPT-11
VAN+RT
VAN+CPT-11+RT

100

The pattern of tumor growth in the group that received the tripletreatment combination reflected both the interaction between
vandetanib and CPT-11 and that between vandetanib and radiation
(as mentioned previously). Thus, during the first week, instead of
the delayed tumor growth seen in the two-treatment combinations,
tumor volume in the triple-treatment combination actually decreased
(p = 0.001 vs. vandetanib plus CPT-11, and 0.052 vs. vandetanib plus
radiation). After that time, similar to the two-treatment combinations
that involved vandetanib, tumor growth started accelerating. By the end
of the third week, tumor growth in the triple-treatment combination
group was similar to that in the two-treatment combination groups
involving vandetanib, and by the fourth week, it was similar to that in the
single-treatment groups.

10
0
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21

28

35

42

Time (days)
Figure 3. Estimated geometric mean tumor volume over time in
LoVo xenografts treated with vandetanib, CPT-11, and/or radiation.
Vandetanib was administered at 50 mg/kg daily orally for 14 days,
starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally
on Days 1 and 3. Radiation was given as three fractions (3x3 Gy)
on Days 1, 2, and 3.

Discussion
During the first week of treatment, animals receiving the combination
of vandetanib with CPT-11 had average daily tumor growth rate of
less than 3.5%, significantly lower than CPT-11 alone and marginally
so compared with vandetanib alone (p = 0.001 and 0.058, respectively,
after 7 days). By the end of the 2-week vandetanib treatment, the
tumor growth rate in the combination group (4.6%) was still significantly
lower than for CPT-11 alone (p = 0.015) but comparable to that for
vandetanib alone (p = 0.682). By the third and fourth weeks, tumor
growth had reached levels similar to those seen in the single-treatment
groups (Fig. 3, Table 1).
The combination of vandetanib with radiation resulted in a similar
pattern of nonlinear tumor growth inhibition. After the first 7 days,
the average daily tumor growth rate of 2.1% was significantly lower

Relatively little is known about the antitumor effects of combining
cytotoxic drugs, radiotherapy, and novel targeted therapies that specifically
interfere with signaling pathways controlling cancer proliferation, angiogenesis, and survival. In the present study, vandetanib, a potent inhibitor
of both VEGFR and EGFR signaling, was combined with CPT-11 or radiation, to determine if greater anti-colorectal tumor activity can be obtained.
This study demonstrated that all three single treatments (vandetanib,
CPT-11, and radiation) significantly slowed LoVo colorectal tumor
growth. Previous studies with single-agent vandetanib demonstrated
that chronic oral administration reduced tumor vascularity and tumor
growth in a variety of xenograft models, including CRC.7, 17 In the clinic,
the safety and tolerability of vandetanib has been demonstrated in
patients with advanced colorectal cancer as well as other solid tumors.18

Table 1. Estimates of the average daily tumor growth rate and average tumor doubling time, by treatment group

__________
1

%Δ(T2x)

__________ __________ __________ __________ __________
7

14

21

28

35

%Δ(T2x)

%Δ(T2x)

%Δ(T2x)

%Δ(T2x)

%Δ(T2x)

8.9 (8.2)

CTR

9.9 (7.4)

CPT-11

7.1 (10.2)

RT

5.6 (12.7)

VAN

5.0 (14.3)

CPT-11 + RT

5.1 (13.9)

VAN + CPT-11
VAN + RT
VAN + CPT-11 + RT

†

Time (days)

0.9 (75.4)

1.9 (37.1)

3.2 (22.2)

4.6 (15.5)

6.0 (11.9)

7.4 (9.7)

2.1 (33.4)

3.4 (20.9)

4.7 (15.2)

6.0 (11.9)

7.3 (9.8)

0.0 N/A

2.4 (28.7)

4.9 (14.5)

7.4 (9.7)

-2.1 N/A

%Δ: estimated average daily rate of increase/decrease of tumor volume (%).
T2x: estimated average doubling time of tumor volume (in days).
N/A: not applicable (tumor shrinks or is stable).

CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth, so their parameters were constant over time. The remaining
groups did not have log-linear tumor growth, so their parameters were changing over time.
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9.9 (7.3)
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Table 2. P-values for comparisons of treatment groups, on days 7, 14, and 21, after the start of treatment
Day 7

Day 14

Day 21

CTR
CPT-11

0.015 vs. CTR; 0.139 vs. RT; 0.043 vs. VAN

RT

0.001 vs. CTR; 0.139 vs. CPT-11; 0.514 vs. VAN

VAN

0.001 vs. CTR; 0.043 vs. CPT-11; 0.514 vs. RT

CPT-11 + RT
VAN + CPT-11
VAN + RT
VAN + CPT-11 + RT

0.001 vs. CPT-11; 0.560 vs. RT
0.001 vs. CPT-11; 0.058 vs. VAN

0.015 vs. CPT-11; 0.682 vs. VAN

0.005 vs. RT; 0.019 vs. VAN

0.080 vs. RT; 0.212 vs. VAN

0.346 vs. CPT-11; 0.395 vs. VAN
0.496 vs. RT; 0.830 vs. VAN

0.001 vs. CPT-11; 0.001 vs. RT;
0.001 vs. VAN
0.001 vs. CPT-11+RT; 0.001 vs.
VAN+CPT-11; 0.052 vs.
VAN+RT

0.001 vs. CPT-11; 0.001 vs. RT;
0.007 vs. VAN
0.001 vs. CPT-11+RT; 0.017 vs.
VAN+CPT-11; 0.407 vs.
VAN+RT

0.011 vs. CPT-11; 0.366 vs. RT;
0.917 vs. VAN
0.766 vs. CPT-11+RT; 0.294 vs.
VAN+CPT-11; 0.868 vs.
VAN+RT

CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth and therefore comparisons do not depend on time.
The remaining groups did not have log-linear tumor growth and therefore comparisons that involve them depend on time.

Vandetanib induced manageable normal tissue toxicities related to
inhibition of EGFR and VEGFR signaling such as diarrhea, rash, and
hypertension.19, 20 The effect of combining radiation and vandetanib on
normal tissue is currently unknown, however it has been shown in both
preclinical and clinical trials that use of VEGF inhibitors with radiation
may result in higher rates of normal tissue toxicity such as induction
of thrombosis, hemorrhage, and bowel toxicities.21–23 In contrast, it was
postulated that combination of radiotherapy with inhibitors of angiogenesis may actually decrease these risks because radiotherapy has been
used to prevent hemorrhage.24 Overall, the investigation of agents such
as vandetanib in combination with radiation in normal tissue is lacking,
and thus will be a major focus in the future.
As previously discussed, single-agent vandetanib has dual tyrosine
kinase inhibitory activity against VEGFR-2 and EGFR, which allows
it to target two key pathways responsible for tumor growth (i.e., tumor

angiogenic signaling, tumor cell proliferation). It has been speculated
that dual suppression may be critical for sustained suppression of tumor
growth, especially because the EGFR and VEGFR pathways are linked
and exhibit cross-talk.25 In addition, vandetanib can also enhance the
antiproliferative activity of selective EGFR inhibitors such as cetuximab,
thereby potentiating suppression of EGFR signaling.17
The present study confirmed that vandetanib, chronically administered
over 2 weeks, slowed tumor growth in a colorectal tumor model, and,
under the dosing conditions of this study, slowed tumor growth to
a greater extent than CPT-11 alone and to a similar level to radiation
alone. Moreover, vandetanib significantly increased the antitumor effects
of CPT-11 and radiation, when given in combination with either of these
treatments. In particular, these treatment combinations resulted in a slow
tumor growth rate during the 2 weeks of vandetanib administration. These
results confirm an earlier study by Troiani et al.,26 in which vandetanib

Figure 4. Hematoxylin and eosin stained
sections of LoVo colorectal xenografts. All
tumors were collected from animals on Day
14 after the start of treatment. Areas of
necrosis are denoted by nec. Magnification
20x. (a) Control (untreated) tumor, showing
2% necrosis. (b) Tumor from animal after
administration of last dose of vandetanib,
showing 15% necrosis. (c) Tumor from
animal after administration of CPT-11 and
RT, showing 20% necrosis. (d) Tumor from
animal after administration of vandetanib and
CPT-11, showing 10% necrosis.
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(25mg/kg/day) administered in combination with CPT-11 exhibited
high antitumor activity in HT29-tumor–bearing nude mice. Troiani et al.
showed a correlation between this dosing schedule and enhanced EGFR
and VEGFR signal inhibition.
In the present study, the triple combination of vandetanib, CPT-11, and
radiation produced the most marked improvement in response in the
LoVo- tumor–bearing mice. The triple treatment produced a measurable
shrinkage of tumors during the first week of treatment. The combination of
vandetanib, chemotherapy (gemcitabine), and radiation has also been
previously shown to significantly inhibit tumor progression in a pancreatic
tumor model.27 Importantly, the present study also investigated the
kinetics of tumor growth, both during and after a course of treatment. It was
demonstrated that the addition of vandetanib significantly enhanced
the initial antitumor effect of chemo-radiation. However, when vandetanib
treatment ended, tumor growth returned to near control (untreated)
levels. Therefore, these data support the rationale of adding an antivascular
agent to cytotoxic therapies and provide valuable information for the
design of therapeutic protocols.
The precise mechanisms leading to initial tumor regression with the
combined therapies in this study are not known. Analysis of interactions
between cytotoxic agents and vandetanib is complex, given that both
the tumor cells and the tumor microenvironment are affected. In this
connection, radiation can kill not only tumor cells but also endothelial
cells of the tumor vasculature, thereby affecting the radiosensitivity of
the tumor (28, 29). In addition, cytotoxic agents have mechanisms of cell
killing that are different from the targeted agent. Both radiation and CPT-11
kill cells through DNA damage. Both chemotherapy and radiation can
also alter cellular signaling pathways by inducing EGFR phosphorylation
and through the growth factor signaling pathway, contribute to tumor
cell proliferation and survival.30–32 Preclinical studies have also shown that
cytotoxic therapy alone, such as radiation, can result in intensification
of angiogenic processes.33 After cytotoxic treatment, upregulation of
vascular growth factors and their receptors occurs, which contributes
to tumor recurrence and progression.34 Direct upregulation of VEGF
after irradiation of various cancer cell lines has been reported.35 Radiation also induces transient tumor hypoxia which results in upregulation
of hypoxia inducible factor-1 (HIF-1) which can stimulate VEGF and
VEGFR-2 expression. Therefore, simultaneous inhibition of both VEGFR
and EGFR signaling through chronic administration of vandetanib in
combination with cytotoxic therapy is expected to suppress the upsurge
in pro-proliferative and angiogenic signaling resulting from CPT-11 and
radiation-induced EGFR and VEGF. This suppression will thereby lead
to inhibition of vascular protective mechanisms and growth factor
mechanisms contributing to tumor regrowth.
The increased tumor growth that was seen in this study after discontinuation of vandetanib suggests that inhibition of angiogenic and proproliferative signaling is readily reversed. The current observations are in
agreement with a number of both preclinical and clinical studies showing
that tumors can adapt to anti-angiogenic treatment by undergoing
‘‘evasive resistance’’ to angiogenesis inhibitors.36 Mechanisms of resistance
include upregulation of alternative proangiogenic signaling pathways as
well as recruitment of bone marrow–derived proangiogenic cells.37, 38
In addition, administration of vandetanib itself has been observed to
increase VEGF production in certain cancer cell lines as well as in tumor
xenografts,39, 40 thereby suggesting an additional contributing mechanism
to tumor relapse. More studies will be needed to determine whether additional angiogenic pathways may be induced by triple modality treatment.
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Conclusions
The results of this study provide a scientific rationale for testing the
combination of vandetanib, CPT-11, and radiation in patients with
CRC. Although the best schedule and sequencing for this triple modality
treatment has yet to be determined, the tumor growth delay kinetics
observed in this study suggest that improvement in colorectal
tumor response can be obtained by concurrent and sustained postsequencing of vandetanib with cytotoxic therapy, keeping in mind
that prolonged chronic administration of the receptor tyrosine kinase
inhibitors may lead to the development of resistance and the requirement
for additional therapeutic agents as seen with other targeted agents,
such as imatinib and gefitinib.41, 42
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